Cancer drug developer ValiRx Plc’s (LON:VAL) joint venture Valiseek has received a US patent for its lead compound VAL401 as a possible treatment for adenocarcinoma cancers.
The drug is targeting non-small-cell lung adenocarcinoma, the most common form of the disease.
A patent has already been awarded for the composition formula for VAL401 and this is further validation of the science behind the treatment, said ValiRx.
Last year, Valiseek appointed clinical trial specialist Clinical Accelerator to carry out work ahead of a Phase IIB study for the lung cancer treatment.
Suzanne Dilly, Valiseek’s chief executive, said: "This further US patent has been allowed at an opportune moment as we progress through our clinical trial preparations.
“At such a late stage in our preparations of the Clinical Trial for VAL401 the fact that the compound is now in receipt of additional IP protection, adds value to shareholder funds and further endorses our joint venture."
Valiseek is a joint venture between ValiRx and Tangent Profiling.